Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer

Yosef Landman; Salomon Marcello Stemmer; Aaron Sulkes; Victoria Neiman; Tal Granot; Daniel Hendler; Mordechai Reuven Kramer; Karen Gelmon; Rinat Yerushalmi

doi:10.1155/2019/2584859

Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer

J Oncol. 2019 Oct 28:2019:2584859. doi: 10.1155/2019/2584859. eCollection 2019.

Authors

Yosef Landman¹, Salomon Marcello Stemmer^{1

2}, Aaron Sulkes^{1

2}, Victoria Neiman¹, Tal Granot¹, Daniel Hendler¹, Mordechai Reuven Kramer^{2

3}, Karen Gelmon⁴, Rinat Yerushalmi^{1

2}

Affiliations

¹ Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
² Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Institute of Pulmonology, Rabin Medical Center, Petach Tikva, Israel.
⁴ Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.

Abstract

Background: Our previous study of pulmonary function in 34 patients with early breast cancer without preexisting lung disease showed that anthracycline- and taxane-based adjuvant dose-dense chemotherapy (DDC) caused a significant 16.4% mean reduction in carbon monoxide diffusing capacity (DLCO). The present study reports the pulmonary and oncological outcomes of these patients on long-term follow-up.

Patients and methods: The primary endpoint was DLCO measured by the pulmonary function test (PFT) performed at a median of 27 months after DDC (range, 8-97) in 25 patients without disease recurrence. DLCO values were recorded as a percentage of predicted values according to age, height, and hemoglobin level and analyzed relative to baseline pre-DDC DLCO values. The secondary endpoints were symptoms, additional therapies, and cancer outcomes during a median of 11 years' follow-up (range, 4.4-11.4).

Results: A longitudinal general linear model showed significant effects of time on DLCO and its trend (F(1, 87) = 14.68, p < 0.001 and F(1, 87) = 10.26, p=0.002, respectively). Complementary descriptive analysis showed a significant recovery on the follow-up PFT (75.6% vs. 81.9%, p=0.002), but it was still significantly lower than the baseline DLCO (81.9% vs. 92.0%, p=0.003). Five patients (20%) still showed a >20% relative DLCO reduction from baseline. Patients with dyspnea or fatigue at later clinical follow-up had a significantly lower DLCO value on the follow-up PFT than nonsymptomatic patients (80.5% vs. 92.1%, p=0.02). DLCO recovery was inversely correlated with age (R = -0.39, p=0.05), but no significant correlation was found with the length of time until the follow-up PFT or additional therapies. There was no association of DDC-related DLCO reduction with cancer outcomes.

Conclusions: The significant reduction in DLCO seen after DDC in patients with potentially curable breast cancer is evident years afterwards, especially in older patients. While most patients partly recover, some will have a lasting symptomatic DLCO impairment.